Sunovion Pharmaceuticals Inc.

Larry Wendell Hardy

Kerry Leigh Spear

Michele L R Heffernan

Frank Wu

Lakshmi D Saraswat

Liming Shao

Michael Charles Hewitt

Jianguo Ma

Fengjiang Wang

Una Campbell

Scott C Malcolm

Patrick Koch

Mark A Varney

Sharon Rae Engel

Larry R Bush

John Emmerson Campbell

Rudy Schreiber

Seth Ribe

Lee W Herman

John E Campell

Scott P Brown

Scott Christopher Malcolm

Michele L Heffernan

Frank Xinhe Wu

Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Dual NAV1.2/5HT2a inhibitors for treating CNS disorders

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Metabotrophic glutamate receptor 5 modulators and methods use thereof

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Cycloalkylamines as monoamine reuptake inhibitors

Metabotrophic glutamate receptor 5 modulators and methods of use thereof

Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.

Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

Tetralone-based monoamine reuptake inhibitors

Growing community of inventors

Sturbridge, MA, United States of America

Larry Wendell Hardy